Virtual Care: A New Era in Neurology

By HEOR Staff Writer

September 6, 2023

As the world grapples with an ageing population and increasing prevalence of chronic diseases, the demand for continuous home and institutional care is expected to rise significantly. This growing need, coupled with the ongoing COVID-19 pandemic, has led to a major advance in the use of virtual care tools. These tools have been instrumental in ensuring access to care and services, promoting continuity of care, and are now being integrated into care pathways for the evaluation, treatment, and follow-up of patients in specialty medicine, particularly neurology.

The Ministère de la Santé et des Services sociaux (MSSS) has initiated a national project on virtual care, mandating the Institut national d’excellence en santé et en services sociaux (INESSS) to provide a state-of-knowledge report to guide the use of virtual care in specialty medicine. This initiative aims to inform public decision-makers, medical associations, and health and social services professionals about virtual care practices in specialty medicine.

The project comprises seven reports, one of which focuses on neurology. The report presents a scoping review of the care pathways that can be supported or optimised with the use of virtual care. The review encompassed scientific and grey literature from the past five years, existing national and international guidelines, guidance and discussion papers, and health technology assessment (HTA) reports.

The findings from the review suggest that telerehabilitation is the most studied intervention across all care pathways. The review also highlights the need for additional good-quality studies to further validate the effectiveness of virtual care interventions.

The report also outlines several care pathways in neurology that have been reported as being clinically effective through the use of virtual care. These include identifying and diagnosing mild and major neurocognitive disorders via teleconsultation, improving cognitive functions through telerehabilitation via videoconferencing, and improving motor functions through physical telerehabilitation via videoconferencing among others.

Despite the promising results, the report also acknowledges the limitations of the study and the need for further research to clarify certain aspects of virtual care. Nevertheless, the findings provide valuable insights into the potential of virtual care in transforming the field of neurology and healthcare as a whole.

As the world continues to navigate through the challenges of the pandemic, the integration of virtual care in healthcare systems worldwide is more important than ever. It is hoped that with continued research and advancements in technology, virtual care will continue to improve access to healthcare and foster patient engagement in managing their illnesses. 

Reference url

Recent Posts

Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS

By HEOR Staff Writer

October 9, 2025

The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse

By João L. Carapinha

October 7, 2025

The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications

By João L. Carapinha

October 6, 2025

The U.S. Food and Drug Administration (FDA) has recently approved lurbinectedin SCLC therapy in combination with atezolizumab, or with atezolizumab and hyaluronidase-qvfc, for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). This regulatory decision reflects ...